1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2020 https ://goldcopd.org/
2. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
3. Lamprecht B., McBurnie M.A., Vollmer W.M., et al., BOLD Collaborative Research Group: COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest 2011;139:752-763.
4. Mehta A.J., Miedinger D., Keidel D. et al., The SAPALDIA Team. Occupational exposure to dusts, gases, and fumes and incidence of chronic obstructive pulmonary disease in the Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults. Am J Respir Crit Care Med 2012;185:1292- 1300.
5. Silva G.E., Sherrill D.L., Guerra S. et al. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004;126:59-65.
6. Brutsche M.H., Downs S.H., Schindler C., Gerbase M.W., Schwartz J., Frey M., Russi E.W., Ackermann-Liebrich U., Leuenberger P.: Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax 2006;61:671-677.
7. de Marco R., Accordini S., Marcon A., Cerveri I., Antó J.M., Gislason T., Heinrich J., Janson C., Jarvis D., Kuenzli N., Leynaert B., Sunyer J., Svanes C., Wjst M., Burney P., European Community Respiratory Health Survey (ECRHS): Risk factors for chronic obstructive pulmonary disease in a European cohort of young adults. Am J Respir Crit Care Med 2011;183:891-897.
8. de Marco R., Accordini S., Cerveri I., Corsico A., Antó J.M., Künzli N., Janson C., Sunyer J., Jarvis D., Chinn S., Vermeire P., Svanes C., Ackermann-Liebrich U., Gislason T., Heinrich J., Leynaert B., Neukirch F., Schouten J.P., Wjst M., Burney P.: Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007;175:32-39.
9. Bridevaux P.O., Gerbase M.W., Probst-Hensch N.M., Schindler C., Gaspoz J.M., Rochat T.: Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax 2008;63:768- 774.
10. Stoller J.K.: Clinical features and natural history of severe alpha-1-antitrypsin deficiency. Chest 1997;111:123S-128S.
11. Stoller J.K., Aboussouan L.S.: A review of alpha- 1-antitrypsin deficiency. Am J Respir Crit Care Med 2012;185:246-259.
12. Smolonska J., Wijmenga C., Postma D.S., Boezen H.M.: Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Crit Care Med 2009;180:618-631.
13. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation// Int J COPD 2014;12:963-74.
14. World Health Organization. Evidence-informed policy-making. 2016. http ://www.who.int/evidence
15. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2011 // www.goldcopd.com.
16. Celli B., MacNee W., ATS/ERS Task Force: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. Eur Respir J 2004;23:932-946.
17. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., Wedzicha J.A.: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999;54:581-586.
18. Jones P.W., Harding G., Berry P., Wiklund I., Chen W.H., Kline Leidy N.: Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34:648-654.
19. Hurst J.R., Vestbo J., Anzueto A., Locantore N., Müllerova H., Tal-Singer R., Miller B., Lomas D.A., Agusti A., Macnee W., Calverley P., Rennard S., Wouters E.F., Wedzicha J.A.: Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010;363:1128-1138.
20. Barnes P.J., Celli B.R.: Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-1185.
21. Hill K., Goldstein R.S., Guyatt G.H. et al. Prevalence and underdiagnosis of chronic obstructive pulmonary diseaseamong patients at risk im primary care // CMAJ 2010;182(7):673-8.
22. Güder G, Brenner S, Angermann CE, et al. "GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". Respir Res. 2012;13(1):13. Published 2012 Feb 6. doi:10.1186/1465-9921-13-13
23. Bhatt SP, Balte PP, Schwartz JE, Cassano PA, Couper D, Jacobs DR Jr, Kalhan R, 0"Connor GT, Yende S, Sanders JL, Umans JG, Dransfield MT, Chaves PH, White WB, Oelsner EC. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization and Mortality. JAMA. 2019 Jun 25;321(24):2438-2447. doi: 10.1001/jama.2019.7233. PMID: 31237643; PMCID: PMC6593636.
24. Tashkin D.P., Celli B., Decramer M., Liu D., Burkhart D., Cassino C. et al. Bronchodilator responsiveness in patients with COPD // Eur Respir J 2008;31:742-50.
25. Ouanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European 80 Community for Steel and Coal. Official Statement of the European Respiratory Society// Eur Respir J. 1993, 6: suppl. 16, 5-40.
26. Wanger J., Clausen J.L., Coates A. et al. Standardisation of the measurement of lung volumes //Eur Respir J 2005;26:511-522.
27. Amalakanti S., Pentakota M.R. Pulse Oximetry Overestimates Oxygen Saturtion in COPD // Respir Care 2016;61(4):423-7.
28. Casanova C., Cote C.G., Marin J.M. et al. Test 6-min walking distance: long-term follow up in patients with COPD//EurRespirJ2007;29(3):535-40.